Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FGBR2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,932
Award facts
- Contract value 100% obligated
- $1,931.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $1,931.83 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/mL auto-injectors. This delivery order, issued without set-aside designation on December 30, 2025, with completion by December 31, 2025, represents a single transaction under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency. The company serves as a regional prime vendor contractor under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy established to provide comprehensive pharmaceutical and medical supply support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, supplying an extensive portfolio of branded and generic pharmaceuticals, biologics, vaccines, and medical consumables to support military healthcare operations. The company's prime vendor contract, awarded November 13, 2025, carries a $499.999 billion ceiling value with a completion date of December 31, 2036, structured with a 30-month base period and three 30-month option periods. This delivery order for Nucala, a biologic immunosuppressant used in treating conditions such as severe asthma and eosinophilic granulomatosis, exemplifies the specialized pharmaceutical requirements the company fulfills as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FGBR2?
SPE2DR26FGBR2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FGBR2 worth?
The government has obligated $1,932 on SPE2DR26FGBR2.
Is contract SPE2DR26FGBR2 an order under another contract?
Yes. SPE2DR26FGBR2 is a delivery order under SPE2DR25D9315, an indefinite delivery contract.
Was contract SPE2DR26FGBR2 competed?
The extent of competition for SPE2DR26FGBR2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award